Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0002871 (anemia)
 52,094 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Prevalence of Isolated Systolic Hypertension (ISH) defined as systolic blood pressure greater than 160 mmHg and diastolic blood pressure less than 90 mmHg was studied in a population of 148 patients treated by hemodialysis whose 80 had undergone ambulatory blood pressure (ABP) recording during the interdialytic period. All patients were treated 3 times 4 hours a week. ABP was recorded for 48 hours between two sessions of hemodialysis using a Delmar Avionic Presurometer (PIV). Prevalence of ISH was 12.5%, while that of systolic-diastolic hypertension (SDH) was 15%. Average age at the time of the study was respectively 59 +/- 13 yrs ISH and 49 +/- 11 yrs SDH (p less than 0.01) while that of patients with normal blood pressure (N) was 57 +/- 10 yrs. Mean duration of HD treatment was no different between groups: 5.3 +/- 3.5 yrs ISH, 5.0 +/- 4.2 yrs SDH and 5.0 +/- 4.3 yrs N. Causes of end-stage renal disease were similar in each group. All patients with ISH and SDH and 42% of N pts were receiving antihypertensive treatment at the time of ABP recording. Finally, level of anemia and percentage of patients treated by EPO were similar in each group.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:[Isolated systolic hypertension in uremic hemodialyzed patients]. 183 61

The rh-EPO is a potent drug to treat renal anaemia. RBC aggregation is not influenced by the rh-EPO therapy. Membrane elasticity and RBC deformability improve remarkably after rh-EPO which might benefit microcirculation. Rh-EPO therapy can not prolong RBC life span. Obviously uremic milieu alone determines RBC life time. Rh-EPO treatment corrects renal anemia by increasing the number of RBC and the RBC volume.
 ...
PMID:Changes in rheology and red blood cell function under recombinant human erythropoietin therapy. 189 2

The peroxidase, alkaline phosphatase, acid phosphatase, beta-glucuronidase and N-acetyl-beta-D-glucosaminidase activity was assessed using a semiquantitative cytochemical methods in peripheral blood neutrophils from 10 maintenance haemodialysed patients treated with recombinant human erythropoietin (rHu EPO) due to severe anaemia. The examination was performed immediately prior to rHu EPO treatment, after 10 weeks and 32 weeks of therapy. A statistically significant increase in the beta-glucuronidase and N-acetyl-beta-D-glucosaminidase activity was observed after 10 weeks, while all the enzymes studied except peroxidase showed a significant elevation of their activity after 32 weeks of the treatment as compared with the values obtained prior to therapy.
 ...
PMID:[Activity of selected neutrophil enzymes of patients maintained on hemodialysis and treated with erythropoietin (rHu EPO)]. 189 3

6 patients with symptomatic renal anaemia treated with haemodialysis (3F, 3M, aged 41 +/- 17 years) were given r-Hu EPO in initial dose of 50 U/kg, modified during the treatment, according to the Hkt, and Hgb values. Some biochemical and rheological properties of blood taken before treatment showed: normochromic and normocytic anemia with Hkt 22.7 +/- 1.7% Hgb 6.81 +/- 1.6 g% and normal reticulocytosis: significant (p less than 0.001) decrease of whole blood viscosity (WBV) at low shear rate (2.25 x sec-1) and high shear rate (225 x sec-1) related to Hkt values, and significant increase of red celles aggregation (RCA) (p less than 0.02) in comparison to healthy persons. Plasma viscosity (PV), serum fibrinogen, protein and albumin were normal. In 4 patients treated with r-Hu EPO for 12 weeks at least, we observed an increase Hkt to 36.7 +/- 2% and Hgb to 11.2 +/- 1.2 g% and a significant increase of WBV at high shear rate (p less than 0.05), normalization of RCA and improvement of the filtrability of whole blood. No side effects were observed, especially insufficient control of blood pressure. Our preliminary results indicate that our treatment of renal anemia with r-Hu EPO was clinically effective, safe and had positive influence on blood rheology.
 ...
PMID:[Effect of erythropoietin on some rheological and biochemical properties of blood in dialysed patients with irreversible kidney failure. Preliminary results]. 189 4

We used RNAase protection assays to measure low levels of erythropoietin messenger RNA (EPO mRNA) in the organs of unstimulated rats, and to compare basal and stimulated levels of EPO mRNA in the kidneys and extrarenal organs of rats rendered uremic by subtotal nephrectomy, with pair-fed controls. Using this sensitive assay, EPO mRNA was measured in the kidneys of unstimulated control animals and was detectable, at lower levels, in the liver and lung. After exposure to hypoxia, there was a 150-fold increase in renal EPO mRNA. Hepatic EPO mRNA was also greatly increased and accounted for 39 +/- 10% of the total. The small quantity of EPO mRNA in lung did not increase, but EPO mRNA became detectable in spleen. Animals subjected to subtotal nephrectomy became uremic and anemic (hematocrit 0.32 +/- 0.04 vs. 0.43 +/- 0.04 in controls, P = 0.002), but serum EPO concentrations were not significantly increased (32 +/- 9 vs. 24 +/- 6 mU/ml, P = 0.14). However, after hypoxic exposure, uremic animals increased serum EPO concentrations greatly, although the response was less than in controls (349 +/- 82 vs. 1009 +/- 238 mU/ml, P = 0.002). After hypoxia, extrarenal EPO mRNA levels in uremic animals were similar to controls. In particular, the large hepatic potential for EPO mRNA synthesis was unchanged but accounted for a greater proportion (84 +/- 5%) of the total EPO mRNA. The renal EPO mRNA content was reduced, as expected, after subtotal nephrectomy, but increased 50-fold after hypoxia. In this model of chronic renal failure, despite anemia, a large potential for EPO synthesis exists in liver and remnant kidney.
 ...
PMID:Organ distribution of erythropoietin messenger RNA in normal and uremic rats. 192 Nov 57

Recombinant human erythropoietin (rhu EPO) is the choice treatment of dialytic anemia; however, this therapy has side effects due to the increased number of blood components involved. It seemed to us worth assessing, by hemorheological study, the impact of such a treatment on blood flow properties, already impaired in this type of patients. This study was designed to measure the evolution of hemorheological parameters in 16 hemodialysed patients before and after 2.3 and 6 months of treatment with rhu EPO. Hemorheological work-ups included: erythrocyte filtration with a hemorheometer; blood and plasma viscosities (LS30), ATP and 2.3 DPG, RBC aggregation (Sefam erythroaggregameter), RBC morphology under a scanning electron microscope; blood counts and full biochemical work-ups were performed to explore renal function. The results showed, besides a significant increase in hemoglobin: normalized rigidity index, reflecting the better deformability of erythrocytes; a moderate increase in blood viscosity with uncorrected hematocrit, becoming significant after 6 months of treatment. This increase however did not reach the values that could be expected with the increased hematocrit (it was probably balanced by improved erythrocyte deformability, which is confirmed by the fact that with corrected hematocrit, blood viscosity decreases during treatment). Studying erythrocyte aggregation in hemodialysed patients reveals, in the absence of any treatment, a decrease in aggregation time and a higher dissociation threshold, which reflects a tendency to erythrocyte hyperaggregation enhanced by erythropoietin.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:[Improvement of hemorheologic parameters in hemodialyzed patients treated with human recombinant erythropoietin]. 194 Jun 57

Mechanisms for the development of anemia and the effects of recombinant human erythropoietin (r-HuEPO) on hematological parameters were studied in new congenital adult type polycystic kidney (DBA/2FG-pcy) mice. The majority of DBA/2FG-pcy mice showed progressive anemia and an elevation of blood urea nitrogen, while a minority showed progressive anemia following polycythemia. Kidneys with numerous cysts in the cortex and medulla occupied virtually the entire abdominal cavity, and the combined kidney weight taken as a percentage of body weight reached 13.5% in the DBA/2FG-pcy mouse. The osmotic fragility of DBA/2FG-pcy mice erythrocytes was significantly increased compared with that of normal control mice. In addition, two-fold increases in serum EPO levels, determined by radioimmunoassay, and a decreased number of colony forming unit-erythroid (CFU-E) were observed in the DBA/2FG-pcy mice. The administration of r-HuEPO during anemia significantly increased the red blood cell count, hemoglobin concentration, hematocrit and reticulocyte percentage in a dose-dependent manner. These findings indicate that anemia in the DBA/2FG-pcy mouse is due to increased fragility of erythrocytes, a deficiency in EPO for the degree of anemia and a decreased number or a decreased response of erythroid progenitor cells. We suggest that the DBA/2FG-pcy mouse is a useful spontaneous model of chronic progressive renal failure.
 ...
PMID:Anemia in new congenital adult type polycystic kidney mice. 194 61

The effects of recombinant human erythropoietin (r-HuEPO) on haematological parameters were studied in rats in which uraemia and anaemia had been induced by gentamicin, an aminoglycoside antibiotic and a nephrotoxic agent. After the occurrence of slight polycythaemia, the red blood cell count, haematocrit and haemoglobin concentration decreased by 20-30% compared with those of the control (saline-injected) rats. At the end of gentamicin treatment, the endogenous serum EPO level had decreased to about 40% compared with that of control rats. Gentamicin-treated rats showed marked elevation of blood urea nitrogen, extensive tubular necrosis in the kidney and haemosiderin deposition in the spleen. In the osmotic fragility test, the fragility of erythrocytes significantly increased compared with that of control rats. These findings indicate that the anaemia induced by gentamicin is due not only to a deficiency of EPO but also to an enhancement of fragility of erythrocytes in an azotaemic environment. The administration of r-HuEPO during anaemia markedly increased red blood cell count, haematocrit and haemoglobin concentration. It is suggested that a gentamicin-treated rat is a useful and convenient anaemic model and r-HuEPO is useful for treatment of anaemia in acute renal failure.
 ...
PMID:Effect of recombinant human erythropoietin on new anaemic model rats induced by gentamicin. 198 98

Recombinant erythropoietin (R-EPO) administered i.v. is effective in correcting anemia in patients on hemodialysis (HD). As subcutaneous (s.c.) or intraperitoneal (i.p.) dosing would be preferable in CAPD patients, we have evaluated its efficacy when given by these routes. Sixteen CAPD patients (mean Hb 7.3 +/- 1.6 g/dl) have been divided into two groups: group A received s.c. self-administered R-EPO (starting dose 92 +/- 35 U/kg/week) two times a week; in group B R-EPO was given i.p. (170 +/- 42 U/kg/week) thrice weekly. The observation period lasted about 12 months. All patients reached a target Hb greater than 10 g/dl. Group A achieved a full response within 9 +/- 2 weeks, group B within 13 +/- 1.7 (p less than 0.005). In group A the starting R-EPO dose was not changed; in group B it was increased to 225 +/- 45 U/kg/week. We observed no differences in the incidence of peritonitis in the two groups. Our findings show that both R-EPO administration routes are safe and efficient in correcting anemia in patients on CAPD. A shorter period of treatment and lower doses of R-EPO seem to be required to achieve the same target Hb level when using the s.c. rather than the i.p. application route.
 ...
PMID:Efficacy of recombinant erythropoietin after subcutaneous or intraperitoneal administration to patients on CAPD. 198 30

EPO is an effective therapy of anaemia in CAPD patients. Monitoring serum iron level during EPO therapy is essential. Hypertension is frequently seen in patients with EPO therapy.
 ...
PMID:Treatment of anaemia in CAPD patients with recombinant human erythropoietin. 198 34


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>